Andrew H Matthews

Dr. Andrew H Matthews

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2013 in Journal of Experimental Medicine
Verified
Journal Article
Open access
RGRadhika Goenka
Radhika Goenka
AMAndrew H Matthews
Andrew H Matthews
BZBochao Zhang
Bochao Zhang
POPatrick J. O’neill
Patrick J. O’neill
JSJean L. Scholz
Jean L. Scholz
MCMichael P. Cancro
Michael P. Cancro
We have assessed the role of B lymphocyte stimulator (BLyS) and its receptors in the germinal center (GC) reaction and affinity maturation. Despite ample BLyS retention on B cells in follicular (FO) regions, the GC microenvironment lacks substantial BLyS. This reflects IL-21–mediated down-regulation of the BLyS receptor TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) on GC B cells, thus limiting their capacity for BLyS binding and retention. Within the GC, FO helper T cells (TFH cells) provide a local source of BLyS. Whereas T cell–derived BLyS is dispensable for normal GC cellularity and somatic hypermutation, it is required for the efficient selection of high affinity GC B cell clones. These findings suggest that during affinity maturation, high affinity clones rely on TFH-derived BLyS for their persistence.

8 July 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
AMAndrew H Matthews
Andrew H Matthews
APAlexander E. Perl
Alexander E. Perl
SLSelina M. Luger
Selina M. Luger
ALAlison W. Loren
Alison W. Loren
SGSaar I. Gill
Saar I. Gill
KPKeith W. Pratz
Keith W. Pratz
CPX-351 and venetoclax and azacitidine (ven/aza) are both indicated as initial therapy for acute myeloid leukemia (AML) in older adults. In the absence of prospective randomized comparisons of these regimens, we used retrospective observational data to evaluate various outcomes for patients with newly diagnosed AML receiving either CPX-351 (n = 217) or ven/aza (n = 439). This study used both a nationwide electronic health record (EHR)-derived de-identified database and the University of Pennsylvania EHR. Our study includes 217 patients who received CPX-351 and 439 who received ven/aza. Paitents receiving ven/aza were older, more likely to be treated in the community, and more likely to have a diagnosis of de novo acute myeloid leukemia. Other baseline covariates were not statistically significantly different between the groups. Median overall survival (OS) for all patients was 12 months and did not differ based on therapy (13 months for CPX-351 vs 11 months for ven/aza; hazard ratio, 0.88; 95% confidence interval, 0.71-1.08; P = .22). OS was similar across multiple sensitivity analyses. Regarding safety outcomes, early mortality was similar (10% vs 13% at 60 days). However, documented infections were higher with CPX-351 as were rates of febrile neutropenia. Hospital length of stay, including any admission before the next cycle of therapy, was more than twice as long for CPX-351. In this large multicenter real-world dataset, there was no statistically significant difference in OS. Prospective randomized studies with careful attention to side effects, quality of life, and impact on transplant outcomes are needed in these populations.

19 June 2023 in American Journal of Hematology
Verified
Journal Article
Closed access
AMAndrew H Matthews
Andrew H Matthews
APAlexander E. Perl
Alexander E. Perl
SLSelina M. Luger
Selina M. Luger
SGSaar I. Gill
Saar I. Gill
CLCatherine Lai
Catherine Lai
KPKeith W. Pratz
Keith W. Pratz

31 July 2008 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
JCJenni E. Crowley
Jenni E. Crowley
JSJean L. Scholz
Jean L. Scholz
WIWilliam J. Quinn Iii
William J. Quinn Iii
JSJason E. Stadanlick
Jason E. Stadanlick
JTJohn F. Treml
John F. Treml
MCMichael P. Cancro
Michael P. Cancro

11 February 2024 in American Journal of Hematology
Verified
Journal Article
Open access
YAYasmin Abaza
Yasmin Abaza
EWEric S. Winer
Eric S. Winer
GMGuru Subramanian Guru Murthy
Guru Subramanian Guru Murthy
RSRory M. Shallis
Rory M. Shallis
AMAndrew H Matthews
Andrew H Matthews
JAJessica K. Altman
Jessica K. Altman
Venetoclax (VEN) combined with hypomethylating agents (HMAs) is the standard of care for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) unfit for intensive chemotherapy. To date, real‐world data published on HMAs plus VEN have been either single‐center studies or using community‐based electronic databases with limited details on mutational landscape, tolerability, and treatment patterns in elderly patients. Therefore, we conducted a multicenter retrospective study to assess the real‐world experience of 204 elderly patients (≥75 years) with newly diagnosed AML treated with HMAs plus VEN from eight academic centers in the United States. Overall, 64 patients achieved complete remission (CR; 38%) and 43 CR with incomplete count recovery (CRi; 26%) for a CR/CRi rate of 64%, with a median duration of response of 14.2 months (95% CI: 9.43, 22.1). Among responders, 63 patients relapsed (59%) with median overall survival (OS) after relapse of 3.4 months (95% CI, 2.4, 6.7). Median OS for the entire population was 9.5 months (95% CI, 7.85–13.5), with OS significantly worse among patients with TP53‐mutated AML (2.5 months) and improved in patients harboring NPM1, IDH1, and IDH2 mutations (13.5, 18.3, and 21.1 months, respectively). The 30‐day and 60‐day mortality rates were 9% and 19%, respectively. In conclusion, HMAs plus VEN yielded high response rates in elderly patients with newly diagnosed AML. The median OS was inferior to that reported in the VIALE‐A trial. Outcomes are dismal after failure of HMAs plus VEN, representing an area of urgent unmet clinical need.

31 January 2025 in Blood Advances
Verified
Journal Article
Open access
XWXin Wang
Xin Wang
PGPhyllis A. Gimotty
Phyllis A. Gimotty
AMAndrew H Matthews
Andrew H Matthews
RMRonac Mamtani
Ronac Mamtani
SLSelina M. Luger
Selina M. Luger
CLCatherine Lai
Catherine Lai
Little is known about the impact of recent advances in acute myeloid leukemia (AML) treatment on racial/ethnic disparities in survival outcomes. We performed a retrospective cohort study of patients with newly diagnosed AML using data from a nationwide electronic health record–derived deidentified database. Patients were categorized based on their diagnosis date relative to venetoclax approval, as pre–novel therapy era (Pre era; 2014-2018; n = 2998) or post–novel therapy era (Post era; 2019-2022; n = 2098). Patients in the Post era were older and had more comorbidities than Pre era. Non-Hispanic Black (NHB) and Hispanic patients were younger and more likely to have lower socioeconomic status than non-Hispanic White (NHW) patients, with no differences in the distributions of key disease features. After accounting for age and comorbidity, overall survival (OS) was higher in patients in Post era than Pre era (adjusted hazard ratio [aHR], 0.90; 95% confidence interval [CI], 0.83-0.96). In Pre era, NHB had a 22% higher hazard of death than NHW (aHR, 1.22; 95% CI, 1.04-1.43), whereas worse OS was not observed for NHB in Post era (aHR, 0.86; 95% CI, 0.69-1.08; predicted 2-year survival, 45.3% vs 39.9%). Utilization of novel therapeutics in frontline therapy did not differ by race/ethnicity. Among patients receiving venetoclax-based induction, particularly those without TP53, RAS, or FLT3-ITD mutations, results suggested higher OS for NHB than NHW patients (aHR, 0.67; 95% CI, 0.45-1.01). Additional studies are needed to elucidate factors contributing to these observed survival differences and to inform strategies to optimize outcomes for all patients with AML.